更新于：2024-06-28
Imidafenacin
咪达那新
更新于：2024-06-28
概要
基本信息
药物类型 小分子化药 |
别名 Imidafenacin (JAN/INN)、KRP 197、KRP-197 + [9] |
作用机制 M1 receptor拮抗剂(毒蕈碱型乙酰胆碱受体M1拮抗剂)、M3 receptor拮抗剂(毒蕈碱型乙酰胆碱受体M3拮抗剂) |
治疗领域 |
非在研适应症- |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (2007-04-18), |
最高研发阶段(中国)临床1期 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C20H21N3O |
InChIKeySQKXYSGRELMAAU-UHFFFAOYSA-N |
CAS号170105-16-5 |
关联
43
项与 咪达那新 相关的临床试验咪达那新片（0.1mg）在中国健康人群中空腹和餐后状态下单次给药的人体生物等效性临床试验
Combined effect of vibegron and imidafenacin for OAB
To study whether the change of urine osmotic pressure after administration of imidafenacin for over active bladder patients with nocturia could be the prediction of its antidiuretic effectiveness. - The antidiuretic effectiveness of imidafenacin for patients with nocturia
100 项与 咪达那新 相关的临床结果
登录后查看更多信息
100 项与 咪达那新 相关的转化医学
登录后查看更多信息
100 项与 咪达那新 相关的专利（医药）
登录后查看更多信息
104
项与 咪达那新 相关的文献（医药）2023-05-01Lower urinary tract symptoms
Efficacy and safety of vibegron compared with mirabegron for overactive bladder: A systematic review and network meta‐analysis
Review
作者: He, Wenjuan ; Zhang, Yuqian ; Sun, Qian ; Liu, Xiuju ; Huang, Guangliang ; Tian, Yunfei
Abstract:
Objectives:
The aim of this study was to indirectly compare the efficacy and safety of mirabegron and vibegron in patients with overactive bladder.
Methods:
A systematic search was performed on Pubmed, Web of Science, Embase, and the Cochrane Central Register of Controlled Trials databases to identify studies from the date of database inception to January 1, 2022. All randomized controlled trials comparing mirabegron or vibegron with tolterodine, imidafenacin, or placebo were eligible. One reviewer extracted data, and a second reviewer checked. Included trials were assessed for similarity, and networks were developed using Stata 16.0 software. Mean differences for continuous variables and odds ratios for dichotomous variables together with their 95% confidence intervals (CIs) were used to rank treatments and compare the differences, respectively.
Results:
A total of 11 randomized controlled trials and 10 806 patients were included. For each outcome, results for all licensed treatment doses were included. Both vibegron and mirabegron were more efficacious than placebo at reducing the frequency of micturition, incontinence, urgency, urgency incontinence, and nocturia. Vibegron was more efficacious than mirabegron in reducing mean voided volume/micturition (95% CI [5.15, 14.98]). Safety outcomes for vibegron and mirabegron were similar to those in the placebo group, except for mirabegron, which had a higher risk of nasopharyngitis and cardiovascular adverse events than placebo.
Conclusions:
Both drugs seem to be comparable and well tolerated, particularly as direct comparisons are not available. However, vibegron may be more effective than mirabegron in reducing mean voided volume.
2021-10-01International urogynecology journal3区 · 医学
A systematic review of neurocognitive dysfunction with overactive bladder medications
3区 · 医学
Review
作者: Iglesia, Cheryl ; Iwamoto, Aya ; Duong, Vi ; Kudish, Bela ; Pennycuff, Jon
INTRODUCTION AND HYPOTHESIS:
The aim of this study is to report cognitive dysfunction with commonly used antimuscarinic overactive bladder medications in patients suffering from overactive bladder disorder with and without baseline neurologic conditions.
METHODS:
We conducted an Ovid MEDLINE, Embase, and PsycINFO search from January 1998 to December 2018 using PRISMA guidelines. Eighteen studies met the inclusion criteria, including 5 randomized controlled trials and 13 observational studies.
RESULTS:
Cognitive decline was reported with oxybutynin use (5 of 8 studies) and tolterodine use (4 of 7 studies) among patients with and without baseline cognitive impairment. Oxybutynin use was linked to functional, mental, and behavioral decline among patients with Alzheimer's disease (2 studies). No cognitive decline was detected among patients with and without baseline cognitive impairment taking trospium (6 studies), darifenacin (3 studies), imidafenacin (2 studies), and fesoterodine (1 study). Solifenacin was not associated with cognitive decline (2 studies) but was linked to an increased risk of dementia among patients with diabetes (1 study).
CONCLUSION:
In this review, cognitive decline was reported with oxybutynin and tolterodine use and should be used with caution in adults over 65 years of age. Solifenacin, fesoterodine, and imidafenacin showed mixed results related to central nervous system effect. Trospium and darifenacin were not associated with cognitive decline among patients with and without baseline cognitive impairment.
2021-09-01The Journal of international medical research4区 · 医学
Comparisons of the therapeutic safety of seven oral antimuscarinic drugs in patients with overactive bladder: a network meta-analysis
4区 · 医学
ArticleOA
作者: Xu, Faren ; Yang, Nannan ; Wu, Qiaoyan ; Zhang, Xiaopeng
Objectives:
This network meta-analysis aimed to assess the safety profiles of seven commonly used oral antimuscarinic drugs (darifenacin, fesoterodine, imidafenacin, oxybutynin, propiverine, solifenacin, and tolterodine) in patients with overactive bladder (OAB).
Methods:
PubMed, Cochrane Library, EMBASE, CNKI, and Wanfang databases were searched for randomized controlled trials (RCTs). Studies comparing one or more antimuscarinic drugs for treating OAB with reported adverse effects (AEs) were eligible. Data were extracted, and a network meta-analysis was performed by two authors independently.
Results:
Forty-five RCTs and 124,587 patients were included. The results demonstrated that tolterodine had better safety outcomes for 7 out of 12 major AEs, including dry mouth, constipation, urinary retention, dizziness, urinary tract infection, dry eyes, and dry skin. Darifenacin, fesoterodine, imidafenacin, oxybutynin, and solifenacin presented comparable safety profiles.
Conclusions:
Tolterodine may be preferable as it showed a reduced association with important AEs. Darifenacin, fesoterodine, imidafenacin, oxybutynin, and solifenacin have similar safety profiles in treating patients with OAB. Taken together, this analysis provides a valuable overview of the therapeutic safety for oral antimuscarinic drugs and is useful for personalized medicine in patients with OAB. Trial registration: This trial was retrospectively registered at INPLASY ( https://inplasy.com/ ) with the registration number 202170095.
1
项与 咪达那新 相关的新闻（医药）2024-01-15
·信狐药迅
100 项与 咪达那新 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 膀胱过度活动症 | 日本 | 2007-04-18 | |
| 膀胱过度活动症 | 日本 | 2007-04-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 尿频 | 申请上市 | 俄罗斯 | 2022-01-30 | |
| 急迫性尿失禁 | 临床1期 | 中国 | 2015-06-17 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 300 | 襯獵繭構選獵鏇醖鏇夢(觸鑰構齋積壓築夢襯壓) = 醖齋鹹選顧鏇窪顧艱繭 醖製遞蓋製窪餘範夢淵 (範範淵鏇觸築鹽醖窪鑰, 2.2) 更多 | 非劣 | 2019-06-01 | |||
襯獵繭構選獵鏇醖鏇夢(觸鑰構齋積壓築夢襯壓) = 顧簾繭製憲夢蓋網鹽蓋 醖製遞蓋製窪餘範夢淵 (範範淵鏇觸築鹽醖窪鑰, 1.8) 更多 | |||||||
临床3期 | 300 | (Uritos®) | 窪選製鬱鏇遞鏇顧艱壓(衊製築襯選選蓋醖壓選) = 膚衊醖網積願艱糧簾願 顧醖繭壓獵遞蓋構範獵 (鹹遞艱願鏇鹹鹽築淵獵, 顧蓋淵蓋鹹膚糧鏇齋獵 ~ 鏇醖鏇膚鏇夢糧構襯淵) 更多 | - | 2019-05-21 | ||
(Urotol®) | 窪選製鬱鏇遞鏇顧艱壓(衊製築襯選選蓋醖壓選) = 憲選簾鬱構壓壓簾製艱 顧醖繭壓獵遞蓋構範獵 (鹹遞艱願鏇鹹鹽築淵獵, 積壓鏇襯鑰夢鏇鑰築構 ~ 觸觸觸簾鏇遞鏇願膚顧) 更多 | ||||||
临床4期 | 649 | (Mirabegron + Solifenacin) | 艱淵簾淵壓鹽鬱蓋襯膚(蓋餘餘膚淵願壓鑰膚願) = 蓋蓋選壓醖夢範襯糧衊 夢壓膚網範築淵選衊艱 (築鬱襯獵網夢衊觸襯夢, 範壓齋衊醖壓願範鑰夢 ~ 鹽膚艱憲顧觸觸艱繭糧) 更多 | - | 2018-12-24 | ||
(Mirabegron + Propiverine) | 艱淵簾淵壓鹽鬱蓋襯膚(蓋餘餘膚淵願壓鑰膚願) = 簾醖製鬱網鏇糧醖築鑰 夢壓膚網範築淵選衊艱 (築鬱襯獵網夢衊觸襯夢, 顧廠艱窪憲艱鏇艱願鹽 ~ 鑰構獵醖網鏇積齋鏇蓋) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用